EA202092951A1 - ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR APPLICATION - Google Patents

ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR APPLICATION

Info

Publication number
EA202092951A1
EA202092951A1 EA202092951A EA202092951A EA202092951A1 EA 202092951 A1 EA202092951 A1 EA 202092951A1 EA 202092951 A EA202092951 A EA 202092951A EA 202092951 A EA202092951 A EA 202092951A EA 202092951 A1 EA202092951 A1 EA 202092951A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
drug conjugates
splicing modulator
drug
methods
Prior art date
Application number
EA202092951A
Other languages
Russian (ru)
Inventor
Эрмира ПАЦОЛЛИ
Сильвия БУОНАМИЧИ
Тхиванка Самаракун
Судип ПРАДЖАПАТИ
Натан Фишкин
Джеймс Паласино
Майкл Силер
Пин ЧЖУ
Эндрю Кук
Питер Смит
Сян Лю
Шелби Эллери
Доминик Рейнолдс
Лихуа ЮЙ
Чжэньхуа У
Шоуюн Пэн
Николас Каландра
Меган Шинан
Юнхун Сяо
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority claimed from PCT/US2019/035015 external-priority patent/WO2019232449A1/en
Publication of EA202092951A1 publication Critical patent/EA202092951A1/en

Links

Abstract

Раскрыты соединения, представляющие собой линкер-лекарственное средство, и конъюгаты антитела и лекарственного средства, которые связываются с опухолевыми мишенями человека. Соединения, представляющие собой линкер-лекарственное средство, и конъюгаты антитела и лекарственного средства содержат фрагмент-лекарственное средство, представляющее собой модулятор сплайсинга. Настоящее изобретение дополнительно относится к способам и композициям для применения в лечении неопластических нарушений путем введения конъюгатов антитела и лекарственного средства, представленных в данном документе. В одном варианте осуществления модулятор сплайсинга предусматривает пладиенолид или производное пладиенолида.Disclosed are linker-drug compounds and antibody-drug conjugates that bind to human tumor targets. Linker-drug compounds and antibody-drug conjugates contain a drug moiety which is a splicing modulator. The present invention further provides methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In one embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

EA202092951A 2018-12-13 2019-05-31 ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR APPLICATION EA202092951A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779324P 2018-12-13 2018-12-13
PCT/US2019/035015 WO2019232449A1 (en) 2018-06-01 2019-05-31 Splicing modulator antibody-drug conjugates and methods of use

Publications (1)

Publication Number Publication Date
EA202092951A1 true EA202092951A1 (en) 2021-09-08

Family

ID=77912682

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092951A EA202092951A1 (en) 2018-12-13 2019-05-31 ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202092951A1 (en)

Similar Documents

Publication Publication Date Title
MX2020012997A (en) Splicing modulator antibody-drug conjugates and methods of use.
EA202190189A1 (en) A CROSS-LINKED DERIVATIVE OF PYRROLOBENZODIAZEPINE DIMER (PBD) AND ITS CONJUGATES
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
EA202190471A1 (en) COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR
EA201691059A1 (en) PEPTIDOMYMETICS COMPOUNDS AND THEIR CONJUGATES CONTAINING ANTIBODY AND MEDICINE
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2016016515A (en) Auristatin derivatives and conjugates thereof.
JOP20210045A1 (en) Herboxidiene antibody-drug conjugates and methods of use
EA202191641A1 (en) ANTIBODY-DRUG CONJUGATE COMBINATION WITH PARP INHIBITOR
EA202192137A1 (en) AMATOXY ANALOGUE CONJUGATE WITH BRANCHED LINKERS
MX2020012679A (en) Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof.
EA201991985A1 (en) CONJUGATES ANTIBODY-MEDICINAL PRODUCT (KALS) BASED ON GDAC INHIBITORS AND USE IN THERAPY
WO2015191568A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
CO2022003703A2 (en) therapeutic conjugates
EA201690321A1 (en) APPLICATION OF ANTIBODY IMMUNOCONG CONTRACT TO MUC1 AND MAITANZINOID FOR THE TREATMENT OF SOLID TUMORS
PE20151603A1 (en) ANTI-LAMP1 ANTIBODIES AND DRUG ANTIBODY CONJUGATES, AND USES OF THEM
EA202090741A1 (en) CONJUGATES OF ANTIBODY TO TISSUE FACTOR AND DRUG AND THEIR APPLICATION IN TREATMENT OF CANCER
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
CY1124183T1 (en) ANTI-SEZ6 DRUG CONJUGATES AND METHODS OF USE
EA202190102A1 (en) ANTIBODY CONJUGATES TO TISSUE FACTORS WITH A DRUG AND THEIR APPLICATION IN THE TREATMENT OF CANCER
EA202092951A1 (en) ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR APPLICATION
MX2021003295A (en) Sulfomaleimide-based linkers and corresponding conjugates.
EA202190125A1 (en) PYRIDOPYRIMIDINONE DERIVATIVES FOR USE AS Axl INHIBITORS
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine